04/26/2024
3:22 PM | Halozyme Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/17/2024
6:22 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/26/2024
6:38 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/15/2024
3:46 PM | Halozyme Therapeutics (Filer)
| Form ARS | |
03/15/2024
3:18 PM | Halozyme Therapeutics (Filer)
| Form DEFA14A | |
03/13/2024
4:22 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/13/2024
3:14 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
|
03/04/2024
3:13 PM | Halozyme Therapeutics (Filer)
| Form PRE 14A | |
02/28/2024
5:49 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/28/2024
3:07 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/20/2024
5:53 PM | Halozyme Therapeutics (Issuer)
LaBrosse Nicole (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/20/2024
5:55 PM | Halozyme Therapeutics (Issuer)
Snyder Mark Howard (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/20/2024
5:59 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/20/2024
5:49 PM | Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/16/2024
4:39 PM | Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/16/2024
4:41 PM | Halozyme Therapeutics (Issuer)
LaBrosse Nicole (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/16/2024
4:47 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/12/2024
5:19 AM | Artisan Partners Limited Partnership (Filed by)
Halozyme Therapeutics (Subject)
| Form SC 13G/A | |
02/01/2024
2:51 PM | Halozyme Therapeutics (Subject)
Invesco Ltd. (Filed by)
| Form SC 13G/A | |
01/17/2024
3:56 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/17/2024
7:10 AM | Halozyme Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/16/2024
3:26 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/13/2023
6:48 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2023
3:40 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/12/2023
3:21 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/14/2023
3:19 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/06/2023
3:04 PM | Halozyme Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/06/2023
3:07 PM | Halozyme Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
10/17/2023
6:28 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/19/2023
3:30 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/07/2023
6:14 AM | Halozyme Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/31/2023
4:35 PM | Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/30/2023
3:23 PM | Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/29/2023
4:35 PM | Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/23/2023
4:08 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/22/2023
3:20 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/17/2023
5:12 PM | Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/17/2023
4:29 PM | Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/16/2023
4:11 PM | Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/15/2023
4:02 PM | Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/14/2023
2:31 PM | Daly James M (Reporting)
Halozyme Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
Protect Yourself While There’s Still Time … (Ad) The next step of the Fed's control is here.
Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week.
Allowing the Fed to tighten its grip on your personal privacy and freedom. 4 simple steps to protect your privacy and money before it’s too late. |
08/11/2023
5:44 PM | Daly James M (Reporting)
Halozyme Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/19/2023
3:10 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/18/2023
3:28 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/22/2023
5:20 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/21/2023
3:36 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/09/2023
1:15 PM | Halozyme Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
05/09/2023
5:09 PM | BIZZARI JEAN-PIERRE (Reporting)
Halozyme Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2023
5:12 PM | Connaughton Bernadette (Reporting)
Halozyme Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2023
5:14 PM | Daly James M (Reporting)
Halozyme Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2023
5:16 PM | Duncan Barbara Gayle (Reporting)
Halozyme Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2023
5:19 PM | Halozyme Therapeutics (Issuer)
Henderson Jeffrey William (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2023
5:21 PM | Halozyme Therapeutics (Issuer)
MATSUI CONNIE (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2023
5:24 PM | Halozyme Therapeutics (Issuer)
Miyashita Akiko Moni (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2023
5:27 PM | Halozyme Therapeutics (Issuer)
Posard Matthew L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
